 Silence Therapeutics PLC LON:SLN is cashed up and ready to pick up the pace in 2021 after a transformational 2020, it told investors. Cash and cash equivalents at the end of 2020, the company had cash and cash equivalents of 37.4mln, since when the company has raised 30.8mln through issuing shares while it is due to receive 29.4mln in the first half of this year from its breakthrough deal with AstraZeneca. 